I'll research ZTS (Zoetis) before writing the preview. Let me gather recent earnings materials, filings, news, and stock price data.I have a good overview. Let me read the most recent earnings materials (Q1 2026 release + call) and the latest news, plus get stock price data.Now let me read the Q1 2026 earnings call transcript for management's commentary on the challenges, and check the latest analyst/news sentiment.Let me grab the most recent news around the upcoming print for analyst positioning.I now have everything I need. Here's the earnings preview.

Zoetis (ZTS) — Q2 2026 Earnings Preview

Reports Thursday, August 6, 2026 (before market open) | Conference call 8:30 a.m. ET

The setup: a "show-me" quarter after a brutal Q1

This is arguably the most important print for Zoetis in years. The stock enters the report deeply out of favor after a Q1 report that shattered the long-held thesis that animal health — and Zoetis specifically — is a recession-resistant, price-taking compounder.

Stock context (why the bar is low): - ZTS closed at $74.41 on Aug 5, down roughly 41% year-to-date (from ~$126 at the start of January). - The damage was concentrated on the Q1 print: shares collapsed from $111.22 on May 6 to $87.31 on May 7 (a ~21% single-day drop) and kept falling to a low near $72 by late June — the company's worst weekly drop on record (~27%). - Sharp underperformance vs. peers YTD: Elanco (ELAN) is actually up ~16% and IDEXX (IDXX) is down ~13%, versus ZTS down ~41%. This is a company-specific/companion-animal-demand story, not a sector wipeout.

Consensus for Q2: the Street is looking for adjusted EPS of ~$1.84 and total sales growth of ~+1.6%. Sentiment is described as gloomy, centered on the Librela franchise and the broader U.S. companion-animal business — but the bar is now low, and any signs of stabilization could support the shares.

The key question for tomorrow: Was Q1 the trough, or the start of a structural reset?

What went wrong in Q1 (the baseline to beat)

Q1 2026 was a genuine negative surprise. Reported revenue was $2.26B (+3% reported, flat organic operational), and adjusted EPS of $1.53 missed the ~$1.61 Street estimate. Management cut full-year guidance. The drivers, per CEO Kristin Peck and CFO Wetteny Joseph:

Pet-owner price sensitivity — years of vet-clinic price inflation finally bit; owners delayed routine visits and traded down to cheaper options.
Falling clinic traffic — vet visits down ~3%; clinic revenue growth (~3%) was entirely price.
Intensified competition on price/promotion in dermatology and parasiticides — more entrants, more aggressive promotion, for longer.
No market expansion — unlike past competitive cycles, new entrants did not grow the overall market, so share shifts hit revenue directly.

The segment split was stark: - U.S. –8% organic (companion animal –11%); International +10% organic (companion animal +7%, livestock +14%). - Companion animal –4% organic; Livestock +12% organic.

Crucially, International's headline growth was flattered by ~$100M shifted out of Q4 2025 into Q1 2026 from the Fiscal Year Alignment (FYA). Ex-that shift, global organic revenue would have declined ~5%, and International would have been flat. Watch this carefully in Q2 — the reported numbers are noisy because of the calendar realignment.

The five things that matter most tomorrow

1. Companion animal stabilization — the whole thesis hinges here

Management insisted the exit rates were improving even as Q1 revenue fell. Watch for confirmation on: - Dermatology (key derm –11% global, U.S. –13%): Apoquel is losing share to lower-priced JAK competitors; Cytopoint is holding up better (low switching). Any sequential stabilization or evidence that promotions are moderating would be a positive. - Simparica franchise (–1% global): Management flagged U.S. share nearing prior-year levels by quarter-end and stable puppy share. A return toward growth here would be an important tell. - Convenia and Cerenia: now facing generic competition and losing meaningful share. Watch whether this bleeds further — and whether generics stay contained to non-core brands (management insists no generics in derm/pain/paras "for the next many years").

2. Librela — the lightning rod

Q1 Librela was $101M (–13%), but management stressed U.S. sequential stabilization (first sequential increase in 6 quarters) with stable patient share and improving vet conversations (helped by the U.K. VMD positive benefit-risk findings).
Comps ease as the year progresses and the long-acting Lenivia/Portela launches are ramping in EU/Canada. Investors will want proof the U.S. stabilization is holding and that OA-pain can inflect back toward growth in 2H. This is the single most-watched franchise into the print.

3. Guidance — hold, cut again, or raise the floor?

Current FY2026 guidance (set May 7): - Revenue $9.68–9.96B (organic operational +2–5%) - Adjusted net income $2.87–2.95B (+2–6%) - Adjusted diluted EPS $6.85–7.00; reported EPS $6.35–6.50

With Q1 organic flat (–5% ex-FYA), the full-year 2–5% guide implies a meaningful 2H ramp, aided by easier comps and the Q4 FYA tailwind (~200–250 bps for the year). The credibility of that ramp is the crux. After a fresh cut in Q1, another cut would be very damaging; simply holding the range (or narrowing to the low end while affirming) may be enough to relieve the low-bar setup. Watch management's language on whether macro/competitive pressure is "persisting" vs. "worsening."

4. Margins, cost program, and the "leveraged P&L"

Q1 adjusted gross margin was 71.8% (–10 bps reported, +140 bps ex-FX) — manufacturing execution has been a bright spot.
Management launched a comprehensive cost & productivity program (restructuring, tighter discretionary spend, procurement/organizational levers) to protect the bottom line as the top line softens. Q1 adjusted EPS still grew 7% (helped ~3 pts by convert-funded buybacks).
Watch for evidence the cost actions are landing and whether they can defend the EPS guide even if revenue disappoints. Note mix headwind: livestock (lower margin) is outgrowing companion animal (higher margin).

5. Pricing and the "new normal" debate

Aggregate 2026 price expectation was cut to 1–2% (from 2–3% originally, and well below the elevated prints of recent years). Management is not cutting list prices but is leaning into point-of-sale affordability/loyalty programs for pet owners and cross-portfolio promotions.
The bigger strategic question analysts (William Blair, BofA) pressed: is this a structural deterioration (less durable, more generic/price-driven, no market growth) or a cyclical macro air-pocket? Management firmly argues it's cyclical and that innovation/differentiation will endure. Tomorrow's tone and any forward market-growth commentary matter for the multiple.

Other items to monitor

International vs. FYA noise: because ~$100M shifted into early 2026, reported International growth will keep looking optically strong. Focus on ex-FYA/underlying figures and any color on the Q4 comp headwind that reverses into 2027 (a ~200–250 bps drag next year, all else equal).
Livestock durability: the clear bright spot (+12% organic in Q1), driven by favorable cattle economics, poultry vaccine demand tied to outbreaks, swine supply recovery, and New World screwworm-related parasiticide use. Watch whether this momentum (mid-to-high-single-digit guide) holds and cushions companion-animal weakness.
Diagnostics: +10% globally in Q1, a resilient "urgent/diagnostic care" category — a proof point for the "demand is intact, spending is shifting" narrative.
Neogen animal genomics acquisition: expected to close 2H 2026; watch for updated timing/accretion commentary. Management reiterated a preference for incremental (not transformational) BD.
Pipeline milestones: 12+ potential blockbusters (CKD, oncology, cardiology, anxiety, obesity), with the next major growth wave expected late 2027 into 2028. Near-term: Cytopoint Plus / long-acting mAbs, Procerta, Convenia RTU. Any pull-forward of renal/oncology timelines would be a positive surprise.
Buybacks/capital allocation: convert-funded repurchases have been supporting EPS; watch for any acceleration given the depressed share price.

Bottom line

Expectations are washed out and positioning is defensive after a ~41% YTD drawdown. The debate is binary: cyclical trough vs. structural re-rate. For the bulls, the ingredients for a relief rally are in place — a low bar, a ~$1.84 EPS consensus, easing 2H comps, cost-program leverage, resilient livestock/diagnostics, and management's claim that U.S. companion-animal franchises (Simparica share, Librela sequential) were already stabilizing by quarter-end. For the bears, another guidance trim, continued derm/paras share loss with no market growth, or evidence that price-driven/generic competition is broadening would confirm the "new normal" fear.

Watch, in order: (1) any change to full-year guidance; (2) U.S. companion-animal organic trend and Librela/Simparica/derm exit rates; (3) tone on whether competitive/macro pressure is stabilizing; and (4) margin/cost-program execution defending the EPS guide. Given the noise from the Fiscal Year Alignment, focus on underlying/ex-FYA figures rather than headline reported growth.

Note: figures above are drawn from Zoetis's Q1 2026 earnings release and call, and market/consensus data through Aug 5, 2026. Consensus estimates (EPS ~$1.84, sales +1.6%) reflect pre-print Street expectations and may vary by data provider.